Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Melanoma 56Carcinoma, Non-Small-Cell Lung 56Carcinoma, Renal Cell 34Neoplasms 33Neoplasm Metastasis 29Colorectal Neoplasms 23Squamous Cell Carcinoma of Head and Neck 22Pancreatic Neoplasms 22Carcinoma, Hepatocellular 21Carcinoma, Transitional Cell 18Lung Neoplasms 17Glioblastoma 15Ovarian Neoplasms 14Triple Negative Breast Neoplasms 13Breast Neoplasms 13Urinary Bladder Neoplasms 11Stomach Neoplasms 11Head and Neck Neoplasms 10Uveal Melanoma 9Recurrence 8Myelodysplastic Syndromes 8Lymphoma 8Leukemia, Myeloid, Acute 8Advanced Cancer 8Small Cell Lung Carcinoma 7Multiple Myeloma 7Kidney Neoplasms 7Hodgkin Disease 7Hematologic Neoplasms 7Glioma 7

Interventions

entinostat 1Pharmacogenomic Testing 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Anatomic Stage III Breast Cancer AJCC v8 × Nivolumab × Clear all
NCT02453620 2026-04-13

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
57 enrolled
BreastOther solid neoplasm

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡